Samsung Biologics Braces for a Second General Strike: After Peaking on Capacity, Delivery Certainty Becomes the New Test

After third-round labor mediation collapsed on October 1, Samsung Biologics' union called a second general strike from October 26 — four times longer than the May walkout that involved about 2,800 employees and cost roughly KRW 150B. The timing collides with the PolyPeptide additional acceptance period (Oct 19–30), an October 26 EGM and Q3 results on October 27. Beyond a first-place 845,000 L footprint and US$22B+ in cumulative orders, 2026 new signings have shifted to incremental add-ons (~US$459M YTD) and the Rockville site still runs near break-even — putting delivery certainty in the spotlight for the world's largest biologics CDMO.

The world's largest biologics CDMO is heading into a delicate window. On October 1, wage mediation between Samsung Biologics and its union broke down for the third time at the Incheon Regional Labor Committee, and the union announced a second general strike from October 26 lasting three weeks — four times the length of the company's first full strike on May 1–5, which involved roughly 2,800 employees (more than half the workforce) and cost about KRW 150B by the company's own account. The strike window overlaps the busiest stretch of Samsung's year: the PolyPeptide tender offer's additional acceptance period (Oct 19–30) is running, an extraordinary general meeting falls on October 26, and Q3 results are due October 27. For a company at historic highs on both capacity and backlog, delivery certainty has become the new exam question.

The dispute: a 6.2% wage offer versus 9.5% plus a KRW 3M lump sum

The dispute centers on pay and personnel policy. Management has offered a 6.2% base-wage increase (consistent with its March proposal) plus interest support for an employee stock-ownership plan tied to a paid capital increase, which it says is worth more than KRW 5M per employee on average. The union is demanding an average 9.5% raise plus a KRW 3M fixed payment, alongside reforms to the performance-pay system and greater transparency in personnel decisions. A deeper trigger was a personnel-document leak in November 2025: the union says the file showed a plan to push out low performers via "voluntary retirement," making HR transparency a core demand alongside wages. Management's warning has been blunt: in biologics manufacturing, even a partial process stoppage means discarding the entire batch; the company said the strike would cause enormous losses and a "fatal" blow to long-term competitiveness.

Strong results, but the order mix tells the other half of the story

The labor rift sits beside a solid scoreboard: H1 2026 revenue of KRW 2.58 trillion (+28% YoY) with a record Q2 of KRW 1.32 trillion; cumulative orders on a minimum-purchase basis have passed US$22.0B, with roughly US$10B remaining in backlog — about three times last year's full-year revenue. But the mix of new wins deserves attention: unlike 2025, which landed two billion-dollar-plus framework contracts, new orders in 2026 total only about US$459M, mostly incremental add-ons from existing customers — the US$262M long-term European contract signed September 10 and the roughly US$68.8M follow-on of October 2 are multi-year supply agreements rather than brand-new master contracts. Hana Securities forecasts Q3 revenue of KRW 1.4063 trillion (+11.8% YoY) with an operating margin near 45.2%, driven mainly by faster-than-expected Plant 5 ramp-up; formal results land October 27. On capacity, the 845,000 L footprint after the Rockville acquisition is the world's largest (Lonza ~741,000 L; WuXi Biologics ~305,000 L), but the US plant runs at about 50% utilization near break-even, with meaningful P&L contribution expected only from 2028.

Editorial view: when "capacity leadership" meets "delivery certainty"

The industry's competitive narrative usually revolves around capacity scale and new technology platforms. Samsung's strike is a reminder that delivery certainty is an asset in its own right. Biologics manufacturing is a continuous process industry — an interrupted cell culture means a scrapped batch, and a supply interruption for an approved product can trigger regulatory supply-chain scrutiny. That is why the May strike cost KRW 150B directly, and why the threat of a strike four times longer erodes something harder to rebuild than revenue: trust. Two spillovers matter for the industry. First, urgency around dual sourcing and regionalized supply will rise, and capacity with weak operational resilience risks marginalization — a potential share opportunity for fully loaded US and European sites and for leading Chinese CDMOs. Second, beyond geopolitics, labor structure and operational resilience are becoming a new dimension of customer due diligence. For Chinese CXOs, this is less a rival's bad news than a mirror: in the next phase of competition, stable delivery, workforce retention and quality culture are the moat.